Amani Erra
Hematology & Oncology · Orland Park, ILNPI 1033526165
Payments from drug & device makers
Across 29 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$206
- Lilly USA, LLC$165
- Mirati Therapeutics, Inc.$119
- Takeda Pharmaceuticals U.S.A., Inc.$117
- Epizyme, Inc.$80
- Johnson & Johnson$57
- plus $83 from 3 others
What the payments were for
- Food & beverage$64878%
- Education$17922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 8 | $206 |
| Lilly USA, LLC | 6 | $165 |
| Mirati Therapeutics, Inc. | 5 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $117 |
| Epizyme, Inc. | 1 | $80 |
| Johnson & Johnson | 3 | $57 |
| Bristol Myers Squibb | 2 | $42 |
| Pfizer | 1 | $24 |
| Merck | 1 | $17 |
How this compares
$827 in reported general payments places this provider in the 25th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 20 | $288,858 |
| SprycelDasatinib | 13 | $155,075 |
| Imatinib Mesylate | 25 | $69,220 |
| Prochlorperazine Maleate | 15 | $149 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Orland Park
- Richard SchilskyBurr Ridge$87.1M
- Edwin PosadasBurr Ridge$70.9M
- Oana DanciuChicago$23.2M
- Shuo MaChicago$20.5M
- Olwen HahnChicago$11.9M
- Christine BestvinaChicago$11.3M
- Russell SzmulewitzChicago$9.8M
- Randy SweisChicago$9.4M
- Hedy KindlerChicago$8.6M
- Reem KarmaliChicago$7.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.